EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NYSE:GSKNYSEGSK)(NASDAQ:AZNNASDAQAZN,(NASDAQ:GILDNASDAQ),(NYSE:BMYBMY) EQNX::TICKER_END

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients   Pelareorep-based therapy demonstrates strong safety profile with new chemotherapy regimen in pancreatic cancer patients   SAN DIEGO, CA and CALGARY, AB – January 22, 2025 – Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), a leading clinical-stage company specializing in […]

PALM BEACH, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The demand for effective pancreatic cancer treatments is and has been undeniably high. The growing number of diagnoses, with the aggressive nature of the disease, fuels the market. This demand is further amplified by rising awareness and a focus on personalized medicine, leading to potentially more targeted and effective therapies. Pancreatic cancer remains a formidable foe, with the American Cancer Society estimating over 66,000 new diagnoses and a staggering 51,750 deaths in the US alone for 2024. This translates to 3% of all cancers and a grim 7% of all cancer fatalities, highlighting the urgent need for improved treatment options. The pancreatic cancer treatment market is driven by several factors, including the rising prevalence of obesity, alcohol consumption, and smoking. These lifestyle factors, combined with the growing geriatric population, are expected to fuel market growth. Additionally, personal or family history of pancreatitis and BRCA2 mutation predisposes individuals to pancreatic cancer, further driving demand for effective treatments. A recent report from S&S Insider said that the Pancreatic Cancer Treatment Market size is expected to reach USD 10.53 billion by 2032 and grow at a CAGR of 15.85%. The report continued: “On the supply side, pharmaceutical companies are actively involved in research and development… Moreover, 322 studies were under clinical trial according to clinicaltrail.com in their 3, and 4 phases. Governments also play a crucial role with increased funding for research initiatives and streamlined regulatory processes can accelerate the development and approval of new treatments. Collaborations between public and private entities foster progress, with the shared goal of improving patient outcomes. The overall market for pancreatic cancer treatments is expected to experience significant growth due to the increasing prevalence of the disease and the ongoing search for effective therapies. The development of innovative approaches… offers hope for patients and presents opportunities for pharmaceutical companies and research institutions.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), GSK plc NYSE: GSKNYSEGSK)(NASDAQ: AZNNASDAQAZN, Gilead Sciences, Inc. (NASDAQ: GILDNASDAQ), Bristol Myers Squibb (NYSE: BMYBMY).

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC) EQNX::TICKER_END

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NYSE:GSKNYSEGSK)(NASDAQ:AZNNASDAQAZN,(NYSE:ABBVNYSE),(NASDAQ:CRDFCRDF) EQNX::TICKER_END

Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approval   Advancing gastrointestinal cancer pipeline underscores potential for additional registration-enabling studies   SAN DIEGO, CA and CALGARY, AB – December 26, 2024 — Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy […]

PALM BEACH, Fla., Dec. 26, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The breast cancer drugs market is experiencing rapid expansion due to the diverse applications of drugs in various breast cancer treatment scenarios. Predominantly utilized before and after surgery, these drugs are pivotal in managing the disease. Significant research efforts are focused on targeted therapies tailored to specific breast cancer types, particularly those characterized by overexpression of human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancers, constituting 15% to 20% of cases, exhibit heightened aggressiveness, necessitating targeted interventions. Targeted drug therapy, including immunotherapy, directly addresses proteins on cancer cells, impeding their growth and proliferation. With HER2-targeted drugs demonstrating efficacy in inhibiting tumor progression, the market witnesses a surge in the development and adoption of such therapies to meet the demand for more effective treatments in combating breast cancer. According to a report from BioSpace, the global breast cancer drugs market size, which was valued at USD 32.93 billion in 2023 is projected to surpass around USD 78.61 billion by 2033, registering a CAGR of 9.09% over the forecast period of 2024 to 2033. North America dominated the market with the largest revenue share of 38.61% in 2023. Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), GSK plc NYSE: GSKNYSEGSK)(NASDAQ: AZNNASDAQAZN, AbbVie (NYSE: ABBVNYSE), Cardiff Oncology, Inc. (NASDAQ: CRDFCRDF).

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NASDAQ:CRDFNASDAQCRDF)(NASDAQ:PSNLNASDAQPSNL,(NASDAQ:TEMNASDAQ),(NASDAQ:CKPTCKPT) EQNX::TICKER_END

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NYSE:NVSNYSENVS)(NYSE:PFENYSEPFE,(NYSE:GSKNYSE),(NYSE:BMYBMY) EQNX::TICKER_END

SAN DIEGO, CA and CALGARY, AB – December 18, 2024 – Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep’s potential in difficult-to-treat gastrointestinal cancers were accepted and will be presented at the 2025 American […]

PALM BEACH, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - One of the most common malignancies in the world today is gastric cancer. The incidence rate is influenced by various factors, including the aging of the population, dietary choices, lifestyle changes, and the prevalence of Helicobacter pylori infection. Growth in the market is driven by an increase in demand for diagnostic tools, therapies, and supporting care in tandem with a rise in the number of diagnosed cases. A recent report from MarketsAndMarkets projected that the global gastric cancer market accounted for USD 3.01 billion in 2023 and is expected to reach USD 18.43 billion by 2034 with a CAGR of 17.92% during the forecast period 2024-2034. The report said: “The market will grow due to the rising incidence of gastric cancer, improvements in diagnostic technologies, emerging treatments and therapies, personalized medicine and precision medicine, government funding and initiatives, and technological advancements in surgery and minimally invasive procedures. Growth in the market is driven by an increase in demand for diagnostic tools, therapies, and supporting care in tandem with a rise in the number of diagnosed cases. For instance, in January 2024, Roche revealed encouraging findings from the Phase III RAINBOW research, which assessed the safety and effectiveness of ramucirumab when combined with chemotherapy to treat advanced stomach or gastroesophageal junction (GEJ) cancer.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), Novartis AG NYSE: NVSNYSENVS)(NYSE: PFENYSEPFE, GSK plc (NYSE: GSKNYSE), Bristol Myers Squibb (NYSE: BMYBMY).

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NYSE:ABBVNYSEABBV)(NASDAQ:BGNENASDAQBGNE,(NASDAQ:HCMNASDAQ),(NASDAQ:ELVNELVN) EQNX::TICKER_END

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NYSE:NVSNYSENVS)(NYSE:MRKNYSEMRK,(NYSE:PFENYSE),(NASDAQ:GLMDGLMD) EQNX::TICKER_END

Overall survival (OS) results from BRACELET-1 corroborate results of previous randomized IND-213 breast cancer study Together, these two studies support the compelling potential of pelareorep-based combination therapy to benefit patients with advanced or metastatic HR+/HER2- breast cancer Oncolytics Biotech is moving forward to secure funding for a registration-enabling study of pelareorep-based therapy in advanced or […]

PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer cells removed during the biopsy are examined to check the presence of progesterone or estrogen receptor proteins. The hormones, i.e. estrogen and progesterone, encourage cancer growth when they bind to these receptors. If these receptors are present, cancers are classified as hormone receptor-positive or hormone receptor-negative (proteins). Breast cancer develops due to reasons, such as BRCA gene mutation and PIK3CA gene mutation etc. Ducts and lobules are the major components of a breast, and everything is held together by the connective tissue which surrounds it. Breast cancer develops where the ducts or lobules are located, and it can spread to other body parts via blood and lymph arteries. Breast cancer is metastasized when it spreads to other body regions. Advanced breast cancer is another word for metastatic breast cancer. Advanced breast cancer is defined in medical terms as breast cancer that has gone beyond the breast to other essential organs in the body, such as the bones, lungs, liver, or brain, to mention a few. Metastatic breast cancer usually develops months or years after a person has finished treatment for an early or locally advanced variety of breast cancer, such as stage I, II, or III. As a result, metastatic breast cancer is also known as distant recurrence. A report from Strategic Market Research predicted that the global metastatic breast cancer treatment market is expected to expand at a CAGR of 10.4% to reach $41.74 billion by 2030 during the period 2021-2030. The report said: “The most commonly prescribed treatments for metastatic breast cancer are chemotherapy and radiation therapy. Both of these treatments help to slow tumor growth. On the other hand, hormone therapy is the most successful treatment since it helps to limit the growth of cancer cells. The metastatic breast cancer treatment market trends like the introduction of more advanced technologies and rising demand for metastatic breast cancer therapies are some of the primary drivers driving the global market's growth.”   Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), Novartis AG NYSE: NVSNYSENVS)(NYSE: MRKNYSEMRK, Pfizer Inc. (NYSE: PFENYSE), Galmed Pharmaceuticals Ltd. (NASDAQ: GLMDGLMD).

Extending Survival: Oncolytics Biotech's Pelareorep Shows Promise In Fighting Metastatic Breast Cancer

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NASDAQ:GOVXNASDAQGOVX)(NYSE:GSKNYSEGSK,(NASDAQ:AZNNASDAQ),(NYSE:MRKMRK) EQNX::TICKER_END

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NASDAQ:KYMRNASDAQKYMR)(NASDAQ:GILDNASDAQGILD,(OTCQX:RHHBY),(NASDAQ:AMGNNASDAQ) EQNX::TICKER_END

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The National Cancer Institute’s (NCI) funding of research projects is predicted to empower the Pancreatic Cancer Market to grow. A report from Future Market Insights said that: “… the increasing adoption of therapeutic strategies is catapulting the pancreatic cancer market forward. Unlike traditional therapeutic methods such as chemotherapy, targeted therapy isolates receptor sites in cancer cells while causing no harm to the body's healthy peripheral cells. The industry is being influenced by the increasing prevalence of pancreatic cancer and the requirement for targeted therapy.” It continued: “The National Cancer Institute has sponsored several research programs dedicated to developing treatments and medications for pancreatic cancer. The Pancreatic Cancer Cohort Consortium, Pancreatic Cancer Cancer Detection Consortium (PCDC), Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC), Pancreatic Cancer Microenvironment Network (PaCMEN), RAS Initiative, Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs), and others are instances of financed projects. These programs each have their mission and targets, and they each seek to find novel solutions to the ailment. The Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs), for instance, is an intervention designed to quickly implement principal scientific discoveries into medical settings. The Pancreatic SPORE grants promote novel and diverse methods of prevention and treatment.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), GeoVax Labs, Inc. NASDAQ: GOVXNASDAQGOVX)(NYSE: GSKNYSEGSK, AstraZeneca PLC (NASDAQ: AZNNASDAQ), Merck (NYSE: MRKMRK).

Demonstrating pelareorep’s synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit  Funding for the study comes from the US$5 million Therapeutic Accelerator Award from PanCAN   SAN DIEGO, CA, and CALGARY, AB – June 20, 2024 — Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), a leading […]

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocarcinoma is expanding in the developed world, and adaptive lifestyle habits such as alcohol and obesity may play a critical role. A report from Future Market Insights projects that the global pancreatic cancer market is projected to accelerate at a CAGR of 13.5% to top US$ 7,541.09 Million by 2033. The report said: “Despite advances in surgical technique, chemotherapy treatments, and the emergence of neoadjuvant chemoradiotherapy, five-year survivorship from this ailment is as low as 2.5% in certain countries. The total number of reported cases of pancreatic cancer in the 7MM nations was around 175,770 in 2021, and this was predicted to increase market growth during the historical period. The upsurge of an unhealthy lifestyle and poor diet has heightened the number of individuals suffering from pancreatic diseases/conditions. The high incidence of diabetes patients has been mainly ascribed to the rising demand for packaged foods and beverages with elevated amounts of sugar, which also significantly contributes to the growing cases of pancreatic cancer patients. Thus, these factors will drive the market growth during the forecast period with a CAGR of 13.5%.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), Kymera Therapeutics, Inc. NASDAQ: KYMRNASDAQKYMR)(NASDAQ: GILDNASDAQGILD, Amgen (NASDAQ: AMGNNASDAQ).

EQNX::TICKER_START (NASDAQONCY),(TSX:ONC),NASDAQ:RENBNASDAQRENB)(NASDAQ:CYTONASDAQCYTO,(NYSE:PFENYSE),(NYSE:ABBVABBV) EQNX::TICKER_END

PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis, and treatment of pancreatic cancer, a particularly aggressive and often fatal form of cancer affecting the pancreas. With its low survival rates and limited treatment options, pancreatic cancer remains a significant focus of medical research and development efforts. A recent report from BioSpace projected that the pancreatic cancer market size which grew to USD 2.05 billion in 2022 is estimated to hit approximately USD 7.4 billion by 2032, with a CAGR of 13.7% for the period of 2023 – 2032. The report said: “This growth is driven by increasing instances of pancreatic cancer and higher investments in pancreatic oncology research. In recent years, the pancreatic cancer market has experienced steady growth, largely driven by the increasing prevalence of pancreatic cancer cases globally. As of 2020, pancreatic cancer ranks as the third most common cause of cancer-related deaths worldwide, with over 64,000 new cases diagnosed in the United States alone in 2023, resulting in over 50,000 deaths.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), Renovaro, Inc. NASDAQ: RENBNASDAQRENB)(NASDAQ: CYTONASDAQCYTO, Pfizer Inc. (NYSE: PFENYSE), AbbVie (NYSE: ABBVABBV).